Quantcast

Latest Mapatumumab Stories

2008-10-23 06:00:11

SOUTH SAN FRANCISCO, Oct. 23 /PRNewswire/ -- Proteolix, Inc., a leader in the discovery and development of novel therapeutics that target protein degradation pathways in cancer and autoimmune diseases, today presented positive data from a Phase 1 clinical trial of carfilzomib (PR-171) in patients with advanced solid tumors at the 20th EORTC-NCI-AACR symposium on "Molecular Targets and Cancer Therapeutics" in Geneva, Switzerland. The Phase 1 clinical trial was designed to assess the safety,...

2008-10-22 09:00:42

AngioChem, Inc., a clinical-stage biotechnology company dedicated to creating and developing new drugs to treat brain diseases, announced today that its lead product, ANG1005, is safe and well tolerated in patients with brain cancer treated to date. ANG1005 consists of a proprietary peptide vector (Angiopep) that transports drugs across the blood-brain barrier (BBB) conjugated to three molecules of the anti-cancer agent paclitaxel. The results, from ongoing Phase I/2 studies in the US and...

2008-10-20 12:00:31

Peregrine Pharmaceuticals, a clinical stage biopharmaceutical company, has completed enrollment in the first stage of its Phase II trial evaluating a combination regimen of bavituximab with carboplatin and paclitaxel in patients with non-small cell lung cancer. In the trial's Simon two-stage design, 21 patients with non-small cell lung cancer have been enrolled in Stage A of the study. The trial may be expanded to include up to a total of 49 patients if promising results are observed in the...

2008-10-20 09:00:08

TUSTIN, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company developing monoclonal antibodies for cancer and serious viral infections, today announced that it has completed enrollment in the first stage of its Phase II trial evaluating a combination regimen of bavituximab with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC). The primary objective of the study is to assess the overall tumor...

2008-10-15 18:00:09

Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that four posters containing data on GSK-923295, an inhibitor of centromere-associated protein E (CENP-E) and data on SB-743921, an inhibitor of kinesin spindle protein (KSP) are scheduled to be presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held from October 21-24, 2008 at the Geneva Palexpo, Geneva, Switzerland. Three of these posters contain preclinical or clinical data relating...

2008-10-09 09:00:10

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) announced today the completion of enrollment as per protocol in the Phase 2 clinical trial of sapacitabine, the Company's oral nucleoside analogue, in elderly patients with acute myeloid leukemia (AML). Interim results from this trial are expected to be available by the end of 2008 and final results during the second half of 2009. "The randomized Phase 2 study of sapacitabine in patients with elderly AML and myelodysplastic...

2008-10-08 09:00:50

Peregrine Pharmaceuticals, a clinical stage biopharmaceutical company, has completed enrollment in the first stage of a Phase II trial of bavituximab in combination with chemotherapy in patients with advanced breast cancer. This is Peregrine's second Phase II study for the treatment of breast cancer. The main objective of the multi-center, open-label, safety and efficacy study is to assess patients' overall response rate to a regimen combining bavituximab with the chemotherapy drugs...

2008-09-30 09:01:00

TransMolecular, a biotechnology company focused on targeted therapies for cancer, has initiated dosing in a Phase I/II trial of 131I-TM601 delivered intravenously for the treatment of adult patients with recurrent malignant glioma. The trial will focus on investigating the tolerability, safety, and therapeutic efficacy of multiple doses of 131I-TM601 when administered intravenously. This study follows the clinical confirmation in a now completed Phase I trial that intravenously...

2008-09-18 12:00:40

S BIO, a biotech company, has initiated multi-center Phase I clinical trials of SB1518, a potent and orally-active JAK2 inhibitor, in patients with leukemia and certain types of lymphoma. These first Phase I trials for SB1518 comprise of ascending dose studies conducted at several leading clinical sites in the US. The trials are expected to enroll up to 60 patients and are designed to determine the maximum tolerated dose and to assess the pharmacokinetics and overall safety profile of...

2008-09-17 15:00:36

European medical scientists have determined a new form of chemotherapy extends the life of patients with inoperable pancreatic cancer. The scientists led by Karolinska Institute Professor Matthias Lohr determined the chemotherapy, which destroys new blood vessels that grow around tumors, produced excellent results in a phase II trial. The researchers said they evaluated the efficacy and safety of three different doses of cationic lipid complexed paclitaxel, or EndoTAG-1, administered...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related